Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourStrong Bearish
15 minBearish
5 minConsolidating
Daily trend turns up above $5.53
Key levels
Resistance$3.19
Resistance$3.00
Support$1.60
Support$1.42
Latest news & SEC filings
DealScancell and Neuphoria Submit Paperwork for Planned Merger
All NEUP news →Neuphoria Therapeutics develops medicines for brain and mental health conditions. Its main drug, BNC210, is taken by mouth and targets a specific receptor in the nervous system; it has been tested in trials for fear- and stress-related illnesses. The company also earns potential payments from drug programs run by other firms, including Merck, Pfizer, and Carina Biotech. It is based in the United States and has ties to Australia.
Based on the company's 10-K filed Sep 18, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NEUP.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$14.62
25
Moat Score
NONE
3/9
Piotroski Score
-8.4
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-92.5%
3yr Revenue CAGR
83.1%
EPS Growth YoY
-1230.43%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for NEUP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:48:56 | $2.70 | 4,500 | $$12K | BUY |
| 14:41:26 | $2.75 | 5,000 | $$14K | MIDPOINT |
| 14:41:13 | $2.75 | 5,000 | $$14K | MIDPOINT |
| 14:41:05 | $2.75 | 4,000 | $$11K | MIDPOINT |
| 14:40:57 | $2.75 | 1,000 | $$3K | SELL |
5 dark pool trades shown · $$53K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Neuphoria Therapeutics Inc. (NEUP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Neuphoria Therapeutics Inc. (NEUP) is at $2.60, down 4.06% (-$0.11) at the Nov 12, 2026 close.
Latest NEUP news — Oct 20, 2026: Scancell and Neuphoria Submit Paperwork for Planned Merger
Analyst ratings for NEUP: 0 Buy, 0 Hold, 1 Sell — consensus Sell.
NEUP last reported on Sep 18, 2026: EPS -$0.56 vs -$0.56 expected — in line.
NEUP does not currently pay a dividend.
Support: $1.60, $1.42, $1.27. Resistance: $3.00, $3.19, $3.42.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Oct 20, 2026: Scancell and Neuphoria Submit Paperwork for Planned Merger